Valeant Pharmaceuticals International, Inc. (NYSE:VRX) closed its last session at $18.37. The stock traded within a range of $17.78 and $18.49. The company operates in the Healthcare sector with a market capitalization of 6.44 Million. Trading volume for Valeant Pharmaceuticals International, Inc. was 6.7 Million in its previous trading session. Currently, Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has an average volume of 16.93 Million.
Valeant Pharmaceuticals International, Inc. is a pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of neurology, dermatology and branded generics. The Company produces medicines that meet the special health problems of patients. Valeant’s development pipeline strategy comprises both new compounds as well as product life cycle management. Its early and late-stage drug candidates have unique formulations and mechanisms of action including retigabine for the treatment of epilepsy and pain, taribavirin of the treatment of chronic hepatitis C, and several dermatology candidates for the treatment of rosacea, acne, and dermatological fungus. Valeant Pharmaceuticals International, Inc. is headquartered in Mississauga, Canada.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) received a Buy rating from 3 analysts. 0 analysts gave its stock an Outperform rating. 6 analysts say it’s a Hold while 0 analysts provided their expert opinion as Sell.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) touched its 1-Year High price of $24.43 on 01/05/18 and its 1-Year Low price of $ 8.31 on 04/24/17.
EPS & Financials
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) reported its EPS in the last quarter as $1.04/Share beating the analyst estimate of $0.89/Share by a difference of $0.15. This showed a surprise of 16.9% in the last quarter earnings.
For the current quarter, 14 analysts are projecting a mean EPS of $0.97/share. According to their observations and findings, the stock could provide a high EPS of $1.29/share and a low EPS of $0.81/share.
Analysts believe that the company has the potential to earn average revenue of $2.17 Billion for the current quarter. According to their predictions high & low revenue estimates are 2.24 Billion and 2.06 Billion respectively.
By taking a look at the stock’s current statistics it can gauged that the stock candle is BULLISH with LOW volatility. Valeant Pharmaceuticals International, Inc. (NYSE:VRX) has a 20-Day average volume of 13.04 Million. According to today’s trading volume Valeant Pharmaceuticals International, Inc. is BELOW its 20-Day Avg. volume with the stock showing BELOW Abnormal volume in the past 150 days.
Moving average convergence divergence (MACD) shows that the stock is on a PRICE RELATIVITY trend. The trend for the past 10-days shows that the company was in BEARISH territory while an analysis of the last 40-Day trend shows a BEARISH signal. The 100-Day trend also shows a BULLISH trend as well.
The company currently has an insider ownership of 2.3 Percent and Institutional ownership of 66.8 Percent. The return on assets stands at 3.3%, Return on Equity currently is 33.8% and the Return on Investment value is -1.6%.
Valeant Pharmaceuticals International, Inc. (NYSE:VRX) gross margin percentage stands at 71.4% while its operating margin for the past trailing twelve month is 5.7 percent and its overall profit margin (ttm) is 15.4 Percent. The stock is currently moving below its 20-Day Simple Moving Average of -5.12% with a 50-Day Simple Moving Average of -10.11 percent. As of today, the company has a SMA200 (200-day simple moving average) of 16.68 Percent. The Stock has YTD (year to date) performance of -11.6 percent.
The TTM operating margin for the company stands at 5.7%. The return on invested capital is at -1.6%, which is good, compared to its peers. The Free Cash Flow or FCF margin is 3.07.
The company’s stock is currently moving with a +ve distance from the 200 day SMA of approximately 16.68%, and has a solid year to date (YTD) performance of -11.6% which means that the stock is constantly adding to its value from the previous fiscal year end price.